Nivolumab + Ipilimumab + Radiation in MSS Pancreatic Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 18, 2020

Primary Completion Date

October 31, 2022

Study Completion Date

October 31, 2026

Conditions
Pancreatic CancerMetastatic Pancreatic Cancer
Interventions
DRUG

Nivolumab

Nivolumab is a type of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack the cancer cells. Nivolumab work by stopping various molecules on cancer cells and body cells from working against the immune system's natural fight against cancer

DRUG

Ipilimumab

Ipilimumab is a type of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack the cancer cells. Ipilimumab work by stopping various molecules on cancer cells and body cells from working against the immune system's natural fight against cancer

RADIATION

Radiation

3D Conformal Radiotherapy to shrink or kill tumors

Trial Locations (3)

02114

Massachusetts General Hospital, Boston

02215

Beth Israel Deaconess Medical Center, Boston

Dana-Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Massachusetts General Hospital

OTHER

NCT04361162 - Nivolumab + Ipilimumab + Radiation in MSS Pancreatic Cancer | Biotech Hunter | Biotech Hunter